Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2009-11-19 Share Issue/Capital Cha…
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans. It includes details about the number of shares to be registered, the plan under which they are offered, and signatures of company officers. This is a capital markets filing related to share registration and issuance under an incentive plan, not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is the registration statement itself, not just an announcement or certification.
2009-11-19 English
Major Shareholding Notification 2009
Major Shareholding Notification
2009-11-17 English
FORM 10-Q
Interim / Quarterly Report Q1 2010
2009-11-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and states that a press release announcing first quarter fiscal year 2010 results is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length is 2648 characters, which is relatively short and consistent with a report announcing an event rather than the full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report filing announcing results but not the full earnings release or detailed financial report itself.
2009-11-12 English
AUTO-GENERATED PAPER DOCUMENT
Annual Report
2009-10-28 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2009-10-13 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.